6218 -- Preserving Patient Access to Home Infusion Act | Poliscope

Preserving Patient Access to Home Infusion Act

6218

116th Congress

In Committee

Preserving Patient Access to Home Infusion Act

Legislative Progress

✓

Introduced

2

Committee

3

Floor Vote

4

Other Chamber

5

Enacted

Introduced

March 12, 2020

Latest Action

March 12, 2020

Primary Sponsor

Eliot L. EngelDemocratic(NY)

Momentum (last 30 days)

0

score

0 actions · 0 new cosponsors · 0 votes

Speed vs cohort

0pct

0d open

vs 9,062 other HR bills in the 116th — cohort avg 39d

Summary

Preserving Patient Access to Home Infusion Act This bill specifically includes pharmacy services and certain self-administered drugs as part of covered home infusion therapy under Medicare, and specifies that certain payment components still apply regardless of whether or not a qualified supplier is physically present in the beneficiary's home.

Lobbying filings that explicitly cite this bill (50)

These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.

Filing registrants (17)

THE NICKLES GROUP, LLC (7)FAEGRE DRINKER BIDDLE & REATH LLP (7)CROSSROADS STRATEGIES, LLC (4)THORN RUN PARTNERS (2)BROWN & FORTUNATO, P.C. (4)THE MCMANUS GROUP (2)FAEGRE BAKER DANIELS CONSULTING (1)BLUE CROSS AND BLUE SHIELD ASSOCIATION (2)BLUE CROSS AND BLUE SHIELD OF FLORIDA INC (2)BLUE CROSS AND BLUE SHIELD OF KANSAS INC (1)

Show 7 more registrants

BLUE CROSS BLUE SHIELD OF MICHIGAN

Subjects (4)

Health care coverage and access

Home and outpatient care

Actions (3)

March 12, 2020

Referred to the Subcommittee on Health.

March 12, 2020

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

March 12, 2020

Introduced in House

Congress.gov source codes: 1000, Intro-H

Committees

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred to	March 12, 2020
Energy and Commerce Committee	House	Referred to	March 12, 2020

Text Versions

Version	Date	Links
Introduced in House	March 12, 2020	XML

Cosponsors (9)

Name	Party	State
Brian K. Fitzpatrick	Republican	PA
Fred Upton	Republican	MI
Joseph D. Morelle	Democratic	NY

Related Bills (1)

Bill	Congress	Relationship
S 3457	116th	Identical bill

Similar Bills (AI)

Bills with similar content found using semantic analysis.

118th

0%

Expressing support for the designation of September 2023 as "National Prostate Cancer Awareness Month".

118th

0%

Expressing support for the designation of May 2024 as "Mental Health Awareness Month".

119th

0%

Expressing support for the designation of June 10 as "FSGS Awareness Day".

Sources: Congress.gov

PREMIER, INC.client→PREMIER, INC.

2021 · first_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Incentivize Domestic Manufacturing Strengthen the SNS Supply Chain Infrastructure Hospital Infrastructure Support Value in Health Care Act of 2020 (H.R. 7791 (116th)) Rural ACO Improvement Act (S. 2648) / Accountable Care in Rural America Act (H.R. 5212) (116th) Electronic Prior Authorization for Medicare Advantage (H.R. 3107 (116th)) Additional Provider Relief Funding Medicare Sequester COVID Moratorium Act (H.R. 315) Long-Term Care Pharmacy Definition Act (S. 4259 (116th)) Preserving Patient Access to Home Infusion Act (S.3457/H.R.6218 (116th)) Black Maternal Health Momnibus Act of 2021 (H.R. 959)

Client expense: $840,000 · Firm income: Not reported

H.R.6218

DUANNE PEARSON SHARA SIEGEL SOUMI SAHA mr BLAIR CHILDS

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

PREMIER, INC.client→PREMIER, INC.

2021 · first_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Incentivize Domestic Manufacturing Strengthen the SNS Supply Chain Infrastructure Hospital Infrastructure Support Value in Health Care Act of 2020 (H.R. 7791 (116th)) Rural ACO Improvement Act (S. 2648) / Accountable Care in Rural America Act (H.R. 5212) (116th) Electronic Prior Authorization for Medicare Advantage (H.R. 3107 (116th)) Additional Provider Relief Funding Medicare Sequester COVID Moratorium Act (H.R. 315) Long-Term Care Pharmacy Definition Act (S. 4259 (116th)) Preserving Patient Access to Home Infusion Act (S.3457/H.R.6218 (116th)) Black Maternal Health Momnibus Act of 2021 (H.R. 959)

Client expense: Not reported · Firm income: Not reported

H.R.6218

DUANNE PEARSON SHARA SIEGEL SOUMI SAHA mr BLAIR CHILDS

Government targets: HOUSE OF REPRESENTATIVES, SENATE

PREMIER, INC.client→PREMIER, INC.

2020 · second_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Lower Health Care Costs Act (S.1895) Reauthorizing and Extending America's Community Health Act - REACH Act (H.R. 2328) Preserve Access to Affordable Generics and Biosimilars Act (S. 64/H.R. 2375) Protecting Jessica Grubbs Legacy Act (S. 1012) Overdose Prevention and Patient Safety Act (H.R. 2062) ACA Medicaid disproportionate share hospital (DSH) cuts Prescription Drug Price Transparency Act (H.R.1035) Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 803) Short on Competition Act (S. 844) Resident Physician Shortage Act of 2019 (H.R. 1763/S. 348) FAST Generics Act (H.R. 985) The Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499) The Fair and Immediate Release of Generic Drugs Act (H.R. 1506) The Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (H.R. 938) The Orange Book Transparency Act of 2019 (H.R. 1503) The Purple Book Continuity Act of 2019 (H.R. 1520) Home infusion: 50401 of the Bipartisan Budget Act of 2018 (BBA) (Pub. L. 115-123) and section 5012 of the 21st Century Cures Act of 2016 (CURES) (Pub. L. 114-255) Phair Pricing Act (H.R. 1030) Improving Seniors' Timely Access to Care Act of 2019 (H.R. 3107) The Mitigating Emergency Drug Shortages (MEDS) Act (S.2723) Accountable Care in Rural America Act (H.R. 5212) Rural ACO Improvement Act (S.2648) Helping Medicaid Offer Maternity Services (H.R. 4996) Prescription Drug Pricing Reduction Act of 2019 (S. 2543) Stop STALLING Act (H.R. 2374) Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209) Preventing Drug Shortages Act (H.R. 6080) Protecting Jessica Grubb's Legacy Act (S. 3374) Preserving Patient Access to Home Infusion Act (H.R. 6218/S. 3457) Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074) Families First Coronavirus Response Act (H.R. 6201) Coronavirus Aid, Relief, and Economic Security Act (H.R. 748) The HEROES Act (HR 6800)

TAKEDA PHARMACEUTICALS AMERICA INCclient→TAKEDA PHARMACEUTICALS AMERICA INC

2020 · fourth_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues; Policies to enhance patient access to medicines in Medicare; Review of proposed rule regarding testing of Medicare part B prescription drug models; Discussions related to rebates and Medicare part D - provisions related to the HHS-OIG Rebate Safe Harbor; Proposals related to amending the protected classes in Medicare; Medicare payment proposals; H.R. 6218, S. 3457, Preserving Patient Access to Home Infusion Act - provisions related to home infusion payment; H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - provisions related to Medicaid drug rebates; S. 551, Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act - provisions related to prescription drug vial sizes and rebates; S. 2543, The Prescription Drug Pricing Reduction Act of 2019 - provisions related to lower prescription drug prices and transparency of pharmaceutical prices and transactions; H.R. 7839, Continuing Access to In-Home IVIG Act - provisions related to patient access; H.R.7783, S.4179, Plasma Donation Awareness Act - provisions related to plasma donation access;

Client expense: $420,000 · Firm income: Not reported

H.R. 6218

Show 46 more cited filings

TAKEDA PHARMACEUTICALS AMERICA INCclient→TAKEDA PHARMACEUTICALS AMERICA INC

2020 · third_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues; Policies to enhance patient access to medicines in Medicare; Review of proposed rule regarding testing of Medicare part B prescription drug models; Discussions related to rebates and Medicare part D - provisions related to the HHS-OIG Rebate Safe Harbor; Proposals related to amending the protected classes in Medicare; Medicare payment proposals; S. 62, The Empowering Medicare Seniors to Negotiate Drug Prices Act - provisions related to Part D and drug pricing negotiation; S. 99, H.R. 448, The Medicare Drug Price Negotiation Act - provisions related to Part D and drug pricing negotiation; H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 - provisions related to Part D and drug pricing negotiation; S. 551, Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act - provisions related to prescription drug vial sizes and rebates; H.R. 4649 Capping Drug Costs for Seniors Act - provisions related to Part D redesign; H.R. 7839, Continuing Access to In-Home IVIG Act - provisions related to patient access; H.R.7783, S.4179, Plasma Donation Awareness Act - provisions related to plasma donation access; H.R. 6218, S. 3457, Preserving Patient Access to Home Infusion Act - provisions related to home infusion payment;

Client expense: $1,190,000 · Firm income: Not reported

H.R. 6218

PREMIER, INC.client→PREMIER, INC.

2020 · fourth_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Lower Health Care Costs Act (S.1895) Reauthorizing and Extending America's Community Health Act - REACH Act (H.R. 2328) Preserve Access to Affordable Generics and Biosimilars Act (S. 64/H.R. 2375) Protecting Jessica Grubbs Legacy Act (S. 1012) Overdose Prevention and Patient Safety Act (H.R. 2062) ACA Medicaid disproportionate share hospital (DSH) cuts Prescription Drug Price Transparency Act (H.R.1035) Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 803) Short on Competition Act (S. 844) Resident Physician Shortage Act of 2019 (H.R. 1763/S. 348) FAST Generics Act (H.R. 985) The Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499) The Fair and Immediate Release of Generic Drugs Act (H.R. 1506) The Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (H.R. 938) The Orange Book Transparency Act of 2019 (H.R. 1503) The Purple Book Continuity Act of 2019 (H.R. 1520) Home infusion: 50401 of the Bipartisan Budget Act of 2018 (BBA) (Pub. L. 115-123) and section 5012 of the 21st Century Cures Act of 2016 (CURES) (Pub. L. 114-255) Phair Pricing Act (H.R. 1030) Improving Seniors' Timely Access to Care Act of 2019 (H.R. 3107) The Mitigating Emergency Drug Shortages (MEDS) Act (S.2723) Accountable Care in Rural America Act (H.R. 5212) Rural ACO Improvement Act (S.2648) Helping Medicaid Offer Maternity Services (H.R. 4996) Prescription Drug Pricing Reduction Act of 2019 (S. 2543) Stop STALLING Act (H.R. 2374) Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209) Preventing Drug Shortages Act (H.R. 6080) Protecting Jessica Grubb's Legacy Act (S. 3374) Preserving Patient Access to Home Infusion Act (H.R. 6218/S. 3457) Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074) Families First Coronavirus Response Act (H.R. 6201) Coronavirus Aid, Relief, and Economic Security Act (H.R. 748) The HEROES Act (HR 6800)

Client expense: $830,000 · Firm income: Not reported

H.R. 6218

DUANNE PEARSON SHARA SIEGEL SOUMI SAHA mr BLAIR CHILDS

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

PREMIER, INC.client→PREMIER, INC.

2020 · third_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Lower Health Care Costs Act (S.1895) Reauthorizing and Extending America's Community Health Act - REACH Act (H.R. 2328) Preserve Access to Affordable Generics and Biosimilars Act (S. 64/H.R. 2375) Protecting Jessica Grubbs Legacy Act (S. 1012) Overdose Prevention and Patient Safety Act (H.R. 2062) ACA Medicaid disproportionate share hospital (DSH) cuts Prescription Drug Price Transparency Act (H.R.1035) Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 803) Short on Competition Act (S. 844) Resident Physician Shortage Act of 2019 (H.R. 1763/S. 348) FAST Generics Act (H.R. 985) The Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499) The Fair and Immediate Release of Generic Drugs Act (H.R. 1506) The Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (H.R. 938) The Orange Book Transparency Act of 2019 (H.R. 1503) The Purple Book Continuity Act of 2019 (H.R. 1520) Home infusion: 50401 of the Bipartisan Budget Act of 2018 (BBA) (Pub. L. 115-123) and section 5012 of the 21st Century Cures Act of 2016 (CURES) (Pub. L. 114-255) Phair Pricing Act (H.R. 1030) Improving Seniors' Timely Access to Care Act of 2019 (H.R. 3107) The Mitigating Emergency Drug Shortages (MEDS) Act (S.2723) Accountable Care in Rural America Act (H.R. 5212) Rural ACO Improvement Act (S.2648) Helping Medicaid Offer Maternity Services (H.R. 4996) Prescription Drug Pricing Reduction Act of 2019 (S. 2543) Stop STALLING Act (H.R. 2374) Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209) Preventing Drug Shortages Act (H.R. 6080) Protecting Jessica Grubb's Legacy Act (S. 3374) Preserving Patient Access to Home Infusion Act (H.R. 6218/S. 3457) Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074) Families First Coronavirus Response Act (H.R. 6201) Coronavirus Aid, Relief, and Economic Security Act (H.R. 748) The HEROES Act (HR 6800)

Client expense: $810,000 · Firm income: Not reported

H.R. 6218

DUANNE PEARSON SHARA SIEGEL SOUMI SAHA mr BLAIR CHILDS

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

BRISTOL-MYERS SQUIBB COMPANYclient→BRISTOL-MYERS SQUIBB COMPANY

2020 · third_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.

Client expense: $1,600,000 · Firm income: Not reported

H.R. 6218

CHRISTOPHER PERNIE GREG CHESMORE JOHN DEOUDES LANE PENRY THOMAS BRUNET mr PAUL WILLIAMS mr RICARDO SANCHEZ ORTEGON

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)

BRISTOL-MYERS SQUIBB COMPANYclient→BRISTOL-MYERS SQUIBB COMPANY

2020 · second_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.

Client expense: $2,160,000 · Firm income: Not reported

H.R. 6218

CHRISTOPHER PERNIE GREG CHESMORE JOHN DEOUDES LANE PENRY STEVE RUBRIGHT THOMAS BRUNET mr PAUL WILLIAMS mr RICARDO SANCHEZ ORTEGON

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)

BRISTOL-MYERS SQUIBB COMPANYclient→BRISTOL-MYERS SQUIBB COMPANY

2020 · fourth_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Most Favored Nation (MFN) Model - (CMS-5528-IFC)

Client expense: $1,090,000 · Firm income: Not reported

H.R. 6218

CHRISTOPHER PERNIE GREG CHESMORE JOHN DEOUDES LANE PENRY THOMAS BRUNET mr PAUL WILLIAMS mr RICARDO SANCHEZ ORTEGON

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)

PREMIER, INC.client→PREMIER, INC.

2020 · fourth_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Lower Health Care Costs Act (S.1895) Reauthorizing and Extending America's Community Health Act - REACH Act (H.R. 2328) Preserve Access to Affordable Generics and Biosimilars Act (S. 64/H.R. 2375) Protecting Jessica Grubbs Legacy Act (S. 1012) Overdose Prevention and Patient Safety Act (H.R. 2062) ACA Medicaid disproportionate share hospital (DSH) cuts Prescription Drug Price Transparency Act (H.R.1035) Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 803) Short on Competition Act (S. 844) Resident Physician Shortage Act of 2019 (H.R. 1763/S. 348) FAST Generics Act (H.R. 985) The Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499) The Fair and Immediate Release of Generic Drugs Act (H.R. 1506) The Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (H.R. 938) The Orange Book Transparency Act of 2019 (H.R. 1503) The Purple Book Continuity Act of 2019 (H.R. 1520) Home infusion: 50401 of the Bipartisan Budget Act of 2018 (BBA) (Pub. L. 115-123) and section 5012 of the 21st Century Cures Act of 2016 (CURES) (Pub. L. 114-255) Phair Pricing Act (H.R. 1030) Improving Seniors' Timely Access to Care Act of 2019 (H.R. 3107) The Mitigating Emergency Drug Shortages (MEDS) Act (S.2723) Accountable Care in Rural America Act (H.R. 5212) Rural ACO Improvement Act (S.2648) Helping Medicaid Offer Maternity Services (H.R. 4996) Prescription Drug Pricing Reduction Act of 2019 (S. 2543) Stop STALLING Act (H.R. 2374) Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209) Preventing Drug Shortages Act (H.R. 6080) Protecting Jessica Grubb's Legacy Act (S. 3374) Preserving Patient Access to Home Infusion Act (H.R. 6218/S. 3457) Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074) Families First Coronavirus Response Act (H.R. 6201) Coronavirus Aid, Relief, and Economic Security Act (H.R. 748) The HEROES Act (HR 6800)

Client expense: Not reported · Firm income: Not reported

H.R. 6218

DUANNE PEARSON SHARA SIEGEL SOUMI SAHA mr BLAIR CHILDS

Government targets: HOUSE OF REPRESENTATIVES, SENATE

BRISTOL-MYERS SQUIBB COMPANYclient→BRISTOL-MYERS SQUIBB COMPANY

2020 · fourth_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Most Favored Nation (MFN) Model - (CMS-5528-IFC)

Client expense: $1,090,000 · Firm income: Not reported

H.R. 6218

CHRISTOPHER PERNIE GREG CHESMORE JOHN DEOUDES LANE PENRY THOMAS BRUNET mr PAUL WILLIAMS mr RICARDO SANCHEZ ORTEGON

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)

PREMIER, INC.client→PREMIER, INC.

2020 · third_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Lower Health Care Costs Act (S.1895) Reauthorizing and Extending America's Community Health Act - REACH Act (H.R. 2328) Preserve Access to Affordable Generics and Biosimilars Act (S. 64/H.R. 2375) Protecting Jessica Grubbs Legacy Act (S. 1012) Overdose Prevention and Patient Safety Act (H.R. 2062) ACA Medicaid disproportionate share hospital (DSH) cuts Prescription Drug Price Transparency Act (H.R.1035) Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 803) Short on Competition Act (S. 844) Resident Physician Shortage Act of 2019 (H.R. 1763/S. 348) FAST Generics Act (H.R. 985) The Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499) The Fair and Immediate Release of Generic Drugs Act (H.R. 1506) The Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (H.R. 938) The Orange Book Transparency Act of 2019 (H.R. 1503) The Purple Book Continuity Act of 2019 (H.R. 1520) Home infusion: 50401 of the Bipartisan Budget Act of 2018 (BBA) (Pub. L. 115-123) and section 5012 of the 21st Century Cures Act of 2016 (CURES) (Pub. L. 114-255) Phair Pricing Act (H.R. 1030) Improving Seniors' Timely Access to Care Act of 2019 (H.R. 3107) The Mitigating Emergency Drug Shortages (MEDS) Act (S.2723) Accountable Care in Rural America Act (H.R. 5212) Rural ACO Improvement Act (S.2648) Helping Medicaid Offer Maternity Services (H.R. 4996) Prescription Drug Pricing Reduction Act of 2019 (S. 2543) Stop STALLING Act (H.R. 2374) Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209) Preventing Drug Shortages Act (H.R. 6080) Protecting Jessica Grubb's Legacy Act (S. 3374) Preserving Patient Access to Home Infusion Act (H.R. 6218/S. 3457) Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074) Families First Coronavirus Response Act (H.R. 6201) Coronavirus Aid, Relief, and Economic Security Act (H.R. 748) The HEROES Act (HR 6800)

Client expense: Not reported · Firm income: Not reported

H.R. 6218

DUANNE PEARSON SHARA SIEGEL SOUMI SAHA mr BLAIR CHILDS

Government targets: HOUSE OF REPRESENTATIVES, SENATE

BRISTOL-MYERS SQUIBB COMPANYclient→BRISTOL-MYERS SQUIBB COMPANY

2020 · third_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.

Client expense: $1,600,000 · Firm income: Not reported

H.R. 6218

CHRISTOPHER PERNIE GREG CHESMORE JOHN DEOUDES LANE PENRY THOMAS BRUNET mr PAUL WILLIAMS mr RICARDO SANCHEZ ORTEGON

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)

BLUE CROSS AND BLUE SHIELD OF KANSAS INCclient→BLUE CROSS AND BLUE SHIELD OF KANSAS INC

2020 · second_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Medicare Advantage; Medicaid Expansion; Medicare Data Sharing; Privacy; Medicare Prescription Drug Pricing; CMS; Generic drugs (CREATES); MACRA; Drug approval; Provider funding; Coronavirus Medicaid Response; Rate Notice and Call Letter; Prior Authorizations, COVID-19 Test Without Cost-Sharing. H.R. 3107 - 116th Congress (2019-2020) Improving Seniors' Timely Access to Care Act of 2019 Sponsor: Rep. Suzan DelBene (D-WA), Rep. Mike Kelly (R-PA), Roger Marshal (R-KS) and Ami Bera (D-CA) H.R. 5833 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to permit the use of certain psychological evaluation via telehealth for Medicare coverage of neurostimulation services for the treatment of chronic pain. Sponsor: Rep. Bob Latta (R-OK-05) H.R. 6179 - 116th Congress - Second Session Increasing Access to Biosimilars Act of 2020 Sponsor: Rep. Tony Cardenas (D-CA-29) H.R. 6218 - 116th Congress - Second Session Preserving Patient Access to Home INfusion Act Sponsor: Rep. Eliot Engel (D-NY-16) H.R. 6214 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to provide for coverage of testing for COVID-19 at no cost sharing under the Medicare Advantage program. Sponsor: Rep. Ron Kind (D-WI-03) H.R. 6484 - 116th Congress - Second Session Care for COVID-19 Act 2.0 Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 6674 - 116th Congress - Second Session Medicare Crisis Program Act of 2020 Sponsor: Rep. Pramila Hayapal. (D-WA-07) H.R. 6739 - 116th Congress - Second Session Ensuring Seniors' Access to COVID Treatments Act Sponsor: Rep. Sean Casten (D-IL-06) H.R. 7062 - 116th Congress - Second Session Affordable Insulin for the COVID-19 Emergency Act Sponsor: Rep. Maxine Waters (D-CA-43) H.R. 6583 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to establish a risk corridor program for Medicare Advantage plans during the COVID-19 emergency, and for other purposes. Sponsor: Rep. Chrissy Houlahan (D-PA-06) H.R. 6640 - 116th Congress - Second Session Medicare Advantage COVID Treatment Act Sponsor: Rep. Debbie Mucarsel-Powell (D-FL-26) H.R. 6837 - 116th Congress - Second Session Medicare Accelerated and Advance Payments IMprovement Act of 2020 Sponsor: Rep. Brad Schneider (D-IL-10) H.R. 7292 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to provide for forgiveness of certain accelerated and advance payments under parts A and B of the Medicare program. Sponsor: Repm. Marcy Kaptur (D-OH-09) H.R. 7323 - 116th Congress - Second Session Medicare Mental Health Inpatient Equity Act of 2019 Sponsor: Rep. Paul Tonko (D-NY-20) H.R. 7338 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to permit the Secretary of Health and Human Services to waive requirements relating to the furnishing of telehealth services under the Medicare program, and for other purposes. Sponsor: Rep. Liz Cheney (R-WY-At-Large) H.R. 5883 - 116th Congress - Second Session Generating Effective and Novel Evidence for Therapy Payment Act Sponsor: Rep. Kurt Schrader (D-OR-05) H.R. 6649 - 116th Congress - Second Session Lower Drug Costs for Seniors During COVID-19 Act of 2020 Sponsor: Rep. Jan Schakowsky (D-IL-09)

Client expense: Not reported · Firm income: Not reported

H.R. 6218

ms SUNEE MICKLE

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

BLUE CROSS AND BLUE SHIELD ASSOCIATIONclient→BLUE CROSS AND BLUE SHIELD ASSOCIATION

2020 · second_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Medicare Advantage; Medicaid Expansion; Medicaid General; Medicare Data Sharing; Privacy; Medicare prescription drug prices, CMS; Generic drugs (CREATES); drug approval; HELP cost reduction package; CHIP; MACRA; Provider funding; Medicaid FMAP Increase; Coronvirus Medicaid Response; Rate Notice and Call Letter H.R.3107 - 116th Congress (2019-2020) Improving Seniors' Timely Access to Care Act of 2019 Sponsor: Rep. Suzan DelBene (D-WA-01) H.R. 5582 - 116th Congress - Second Session Parental Accessibility Rights for Emergency and Negligent Treatment Act Sponsor: Rep. Greg Murphy (R-NC-03) H.R. 5741 - 116th Congress - Second Session Strengthening Innovation in Medicare and Medicaid Act Sponsor: Rep. Terri Sewell (D-AL-07) H.R. 5897 - 116th Congress - Second Session Preventing Abuse and Neglect of Vulnerable Americans Act of 2020 Sponsor: Rep. Ruben Gallego (D-AZ-07) H.R. 5900 - 116th Congress - Second Session Accelerating Kids' Access to Care Act Sponsor: Rep. Joe Kennedy III (D-MA-04) H.R. 6098 - 116th Congress - Second Session To amend title XXI of the Social Security Act to allow States to expand income eligibility standards under the Children's Health Insurance Program, and for other purposes. Sponsor: Rep. Nanette Barragan (D-CA-44) H.R. 6273 - 116th Congress - Second Session Protecting Vulnerable Americans in Times of Crisis Act of 2020 Sponsor: Rep. G.K. Butterfield (D-NC-01) H.R. 5693 - 116th Congress - Second Session Primary Health Services Enhancement Act Sponsor: Rep. Ron Kind (D-WI-03) H.R. 5833 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to permit the use of certain psychological evaluation via telehealth for Medicare coverage of neurostimulation services for the treatment of chronic pain. Sponsor: Rep. Bob Latta (R-OH-05) H.R. 6147 - 116th Congress - Second Session Help Extend Auditory Relief (HEAR) Act of 2020 Sponsor: Rep. Matt Cartwright (D-PA-08) H.R. 6179 - 116th Congress - Second Session Increasing Access to Biosimilars Act of 2020 Sponsor: Rep. Tony Cardenas (D-CA-29) H.R. 6218 - 116th Congress - Second Session Preserving Patient Access to Home Infusion Act Sponsor: Rep. Eliot Engel (D-NY-16) H.R. 5534 116th Congress - First Session Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019 Sponsor: Rep. Ron Kind (D-WI-03) H.R. 6214 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to provide for coverage of testing for COVID-19 at no cost sharing under the Medicare Advantage program. Sponsor: Rep. Ron Kind (D-WI-03) H.R. 6282 - 116th Congress - Second Session Commission on America's Medical Security Act Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 6462 - 116th Congress - Second Session Emergency Medicaid for Coronavirus Treatment Act Sponsor: Rep. Ruben Gallego (D-AZ-07) H.R. 6486 - 116th Congress - Second Session Care for COVID-19 Act 2.0 Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 6495 - 116th Congress - Second Session Insular Area Medicaid Parity Act Sponsor: Del. Gregorio Kilili Camacho Sablan (D-MP At-Large) H.R. 6616 - 116th Congress - Second Session Stronger Medicaid Response to the COVID-19 Pandemic Act Sponsor: Rep. Tony Cardenas (D-CA-29) H.R. 6658 - 116th Congress - Second Session Insular Area Medicaid Coronavirus Recovery Act Sponsor: Del. Gregorio Kilili Camacho Sablan (D-MP At-Large) H.R. 6674 - 116th Congress - Second Session Medicare Crisis Program Act of 2020 Sponsor: Rep. Pramila Jayapal (D-WA-07) H.R. 6739 - 116th Congress - Second Session Ensuring Seniors' Access to COVID Treatments Act Sponsor: Rep. Sean Casten (D-IL-06) H.R. 7062 - 116th Congress - Second Session Affordable Insulin for the COVID-19 Emergency Act Sponsor: Rep. Maxine Waters (D-CA-43) H.R. 7127 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to make technical amendments to the separate payment under the Medicare program for disposable negative pressure wound therapy devices. Sponsor: Rep. G.K. Butterfield (D-NC-01) H.R. 7154 - 116th Congress - Second Session Outpatient Therapy Modernization and Stabilization Act Sponsor: Brendan Boyle (D-PA-02) H.R. 6583 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to establish a risk corridor program for Medicare Advantage plans during the COVID-19 emergency, and for other purposes. Sponsor: Rep. Chrissy Houlahan (D-PA-06) H.R. 6640 - 116th Congress - Second Session Medicare Advantage COVID Treatment Act Sponsor: Rep. Debbie Mucarsel-Powell (D-FL-26) H.R. 6837 - 116th Congress - Second Session Medicare Accelerated and Advance Payments Improvement Act of 2020 Sponsor: Rep. Brad Schneider (D-IL-10) H.R. 7292 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to provide for forgiveness of certain accelerated and advance payments under parts A and B of the Medicare program. Sponsor: Rep. Marcy Kaptur (D-OH-09) H.R. 7323 - 116th Congress - Second Session Medicare Mental Health Inpatient Equity Act of 2019 Sponsor: Rep. Paul Tonko (D-NY-20) H.R. 7338 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to permit the Secretary of Health and Human Services to waive requirements relating to the furnishing of telehealth services under the Medicare program, and for other purposes. Sponsor: Rep. Liz Cheney (R-WY-At-Large) H.R. 5882 - 116th Congress - Second Session Generating Effective and Novel Evidence for Therapy Payment Act Sponsor: Rep. Kurt Schrader (D-OR-05) H.R. 6159 - 116th Congress - Second Session Kids' Access to Primary Care Act of 2020 Sponsor: Rep. Kim Schrier (D-WA-08) H.R. 6281 - 116th Congress - Second Session Medicare Wage Index Parity Act of 2020 Sponsor: Rep. Bill Pascrell (D-NJ-09) H.R. 6649 - 116th Congress - Second Session Lower Drug Costs for Seniors During COVID-19 Act of 2020 Sponsor: Rep. Jan Schakowsky (D-IL-09)

Client expense: $1,690,000 · Firm income: Not reported

H.R. 6218

ANDREW PATZMAN DAVID TULLY JASON PRAY JUSTINE HANDELMAN KRIS HALTMEYER MISTI MILLER VERONICA JACKSON mr PHILIP HAYS

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

BLUE CROSS BLUE SHIELD OF MICHIGANclient→BLUE CROSS BLUE SHIELD OF MICHIGAN

2020 · second_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Medicare Advantage; Medicaid Expansion; Medicaid General; Medicare Data Sharing; Privacy; Medicare prescription drug prices, CMS; Generic drugs (CREATES); drug approval; HELP cost reduction package; CHIP; MACRA; Provider funding; Medicaid FMAP Increase; Coronvirus Medicaid Response; Rate Notice and Call Letter H.R.3107 - 116th Congress (2019-2020) Improving Seniors' Timely Access to Care Act of 2019 Sponsor: Rep. Suzan DelBene (D-WA-01) H.R. 5741 - 116th Congress - Second Session Strengthening Innovation in Medicare and Medicaid Act Sponsor: Rep. Terri Sewell (D-AL-07) H.R. 5900 - 116th Congress - Second Session Accelerating Kids' Access to Care Act Sponsor: Rep. Joe Kennedy III (D-MA-04) H.R. 6098 - 116th Congress - Second Session To amend title XXI of the Social Security Act to allow States to expand income eligibility standards under the Children's Health Insurance Program, and for other purposes. Sponsor: Rep. Nanette Barragan (D-CA-44) H.R. 6273 - 116th Congress - Second Session Protecting Vulnerable Americans in Times of Crisis Act of 2020 Sponsor: Rep. G.K. Butterfield (D-NC-01) H.R. 5833 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to permit the use of certain psychological evaluation via telehealth for Medicare coverage of neurostimulation services for the treatment of chronic pain. Sponsor: Rep. Bob Latta (R-OH-05) H.R. 6179 - 116th Congress - Second Session Increasing Access to Biosimilars Act of 2020 Sponsor: Rep. Tony Cardenas (D-CA-29) H.R. 6218 - 116th Congress - Second Session Preserving Patient Access to Home Infusion Act Sponsor: Rep. Eliot Engel (D-NY-16) h.R. 6214 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to provide for coverage of testing for COVID-19 at no cost sharing under the Medicare Advantage program. Sponsor: Rep. Ron Kind (D-WI-03) H.R. 6282 - 116th Congress - Second Session Commission on America's Medical Security Act Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 6462 - 116th Congress - Second Session Emergency Medicaid for Coronavirus Treatment Act Sponsor: Rep. Ruben Gallego (D-AZ-07) H.R. 6486 - 116th Congress - Second Session Care for COVID-19 Act 2.0 Sponsor: Rep. Raul Ruiz (D-CA-36) H.R. 6616 - 116th Congress - Second Session Stronger Medicaid Response to the COVID-19 Pandemic Act Sponsor: Rep. Tony Cardenas (D-CA-29) H.R. 6658 - 116th Congress - Second Session Insular Area Medicaid Coronavirus Recovery Act Sponsor: Del. Gregorio Kilili Camacho Sablan (D-MP At-Large) H.R. 6674 - 116th Congress - Second Session Medicare Crisis Program Act of 2020 Sponsor: Rep. Pramila Jayapal (D-WA-07) H.R. 6739 - 116th Congress - Second Session Ensuring Seniors' Access to COVID Treatments Act Sponsor: Rep. Sean Casten (D-IL-06) H.R. 7062 - 116th Congress - Second Session Affordable Insulin for the COVID-19 Emergency Act Sponsor: Rep. Maxine Waters (D-CA-43) H.R. 7127 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to make technical amendments to the separate payment under the Medicare program for disposable negative pressure wound therapy devices. Sponsor: Rep. G.K. Butterfield (D-NC-01) H.R. 6640 - 116th Congress - Second Session Medicare Advantage COVID Treatment Act Sponsor: Rep. Debbie Mucarsel-Powell (D-FL-26) .R. 6837 - 116th Congress - Second Session Medicare Accelerated and Advance Payments Improvement Act of 2020 Sponsor: Rep. Brad Schneider (D-IL-10) H.R. 7292 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to provide for forgiveness of certain accelerated and advance payments under parts A and B of the Medicare program. Sponsor: Rep. Marcy Kaptur (D-OH-09) H.R. 7323 - 116th Congress - Second Session Medicare Mental Health Inpatient Equity Act of 2019 Sponsor: Rep. Paul Tonko (D-NY-20) H.R. 7338 - 116th Congress - Second Session To amend title XVIII of the Social Security Act to permit the Secretary of Health and Human Services to waive requirements relating to the furnishing of telehealth services under the Medicare program, and for other purposes. Sponsor: Rep. Liz Cheney (R-WY-At-Large) H.R. 5882 - 116th Congress - Second Session Generating Effective and Novel Evidence for Therapy Payment Act Sponsor: Rep. Kurt Schrader (D-OR-05) H.R. 6159 - 116th Congress - Second Session Kids' Access to Primary Care Act of 2020 Sponsor: Rep. Kim Schrier (D-WA-08) H.R. 6281 - 116th Congress - Second Session Medicare Wage Index Parity Act of 2020 Sponsor: Rep. Bill Pascrell (D-NJ-09) H.R. 6649 - 116th Congress - Second Session Lower Drug Costs for Seniors During COVID-19 Act of 2020 Sponsor: Rep. Jan Schakowsky (D-IL-09)

Client expense: $104,240 · Firm income: Not reported

H.R. 6218

Government targets: HOUSE OF REPRESENTATIVES, SENATE

PREMIER, INC.client→PREMIER, INC.

2020 · second_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Lower Health Care Costs Act (S.1895) Reauthorizing and Extending America's Community Health Act - REACH Act (H.R. 2328) Preserve Access to Affordable Generics and Biosimilars Act (S. 64/H.R. 2375) Protecting Jessica Grubbs Legacy Act (S. 1012) Overdose Prevention and Patient Safety Act (H.R. 2062) ACA Medicaid disproportionate share hospital (DSH) cuts Prescription Drug Price Transparency Act (H.R.1035) Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 803) Short on Competition Act (S. 844) Resident Physician Shortage Act of 2019 (H.R. 1763/S. 348) FAST Generics Act (H.R. 985) The Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499) The Fair and Immediate Release of Generic Drugs Act (H.R. 1506) The Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (H.R. 938) The Orange Book Transparency Act of 2019 (H.R. 1503) The Purple Book Continuity Act of 2019 (H.R. 1520) Home infusion: 50401 of the Bipartisan Budget Act of 2018 (BBA) (Pub. L. 115-123) and section 5012 of the 21st Century Cures Act of 2016 (CURES) (Pub. L. 114-255) Phair Pricing Act (H.R. 1030) Improving Seniors' Timely Access to Care Act of 2019 (H.R. 3107) The Mitigating Emergency Drug Shortages (MEDS) Act (S.2723) Accountable Care in Rural America Act (H.R. 5212) Rural ACO Improvement Act (S.2648) Helping Medicaid Offer Maternity Services (H.R. 4996) Prescription Drug Pricing Reduction Act of 2019 (S. 2543) Stop STALLING Act (H.R. 2374) Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209) Preventing Drug Shortages Act (H.R. 6080) Protecting Jessica Grubb's Legacy Act (S. 3374) Preserving Patient Access to Home Infusion Act (H.R. 6218/S. 3457) Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074) Families First Coronavirus Response Act (H.R. 6201) Coronavirus Aid, Relief, and Economic Security Act (H.R. 748) The HEROES Act (HR 6800)

Client expense: $540,000 · Firm income: Not reported

H.R. 6218

DUANNE PEARSON SHARA SIEGEL SOUMI SAHA THOMAS RATLIFF mr BLAIR CHILDS

Government targets: HOUSE OF REPRESENTATIVES, SENATE

BRISTOL-MYERS SQUIBB COMPANYclient→BRISTOL-MYERS SQUIBB COMPANY

2020 · second_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.

Client expense: $2,160,000 · Firm income: Not reported

H.R. 6218

CHRISTOPHER PERNIE GREG CHESMORE JOHN DEOUDES LANE PENRY STEVE RUBRIGHT THOMAS BRUNET mr PAUL WILLIAMS mr RICARDO SANCHEZ ORTEGON

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)

GUIDEWELL MUTUAL HOLDING CORPORATIONclient→GUIDEWELL MUTUAL HOLDING CORPORATION

2020 · second_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Medicare Advantage; Medicaid Expansion; Medicaid; Medicare Data Sharing; Privacy; Medicare Prescription Drug Prices; CMS; Generic Drugs (CREATES Act); Drug Approval; HELP Cost Reduction Package; CHIP, MACRA; Provider Funding; Medicaid FMAP Increase; Coronavirus Medicaid Response; Rate Notice and Call Letter HR 3107 (116th Congress), Improving Seniors Timely Access to Care Act of 2019, by Rep. Suzan DelBene (D-WA). Establish requirements with respect to the use of prior authorization under Medicare Advantage plans. HR 5534 (116th Congress), Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019, by Rep. Ron Kind (D-WI). Provide for extended months of Medicare coverage of immunosuppressive drugs for kidney transplant patients. HR 5582 (116th Congress), Parental Accessibility Rights for Emergency and Negligent Treatment Act, by Rep. Gregory Murphy (R-NC). Expands the scope of advance directive policies and related disclosures for providers under Medicaid and the Children's Health Insurance Program (CHIP). HR 5693 (116th Congress), Primary Health Services Enhancement Act, by Rep. Ron Kind (D-WI). Expand Medicare Rural Health Clinic Services and Federally Qualified Health Center Services to include physical therapy services. HR 5741 (116th Congress), Strengthening Innovation in Medicare and Medicaid Act, by Rep. Terri Sewell (D-AL). Clarify parameters for model testing and add accountability to model expansion under the Center for Medicare and Medicaid Innovation. HR 5833 (116th Congress), by Rep. Bob Latta (R-OH). Permit the use of certain psychological evaluation via telehealth for Medicare coverage of neurostimulation services for the treatment of chronic pain. HR 5882 (116th Congress), GENE Therapy Payment Act, by Rep. Kurt Schrader (D-OR). Provide States with the option under the Medicaid program to pay for covered outpatient drugs through risk-sharing value-based agreements. HR 5897 (116th Congress), Preventing Abuse and Neglect of Vulnerable Americans Act of 2020, by Rep. Ruben Gallego (D-AZ). Requires the Centers for Medicare & Medicaid Services (CMS) to publish specified information on its website relating to deficiencies of Medicaid intermediate care facilities for individuals with intellectual disabilities, including information regarding inspections, complaints, and administrative actions. HR 5900 (116th Congress), Accelerating Kids' Access to Care Act, by Rep. Joseph Kennedy (D-MA). Requires state Medicaid programs to establish a process through which qualifying out-of-state providers may enroll as participating providers without undergoing additional screening requirements. HR 6098 (116th Congress), by Rep. Nanette Diaz Barragan (D-CA). Allow States to expand income eligibility standards under the Childrens Health Insurance Program. HR 6147 (116th Congress), Help Extend Auditory Relief (HEAR) Act of 2020, by Rep. Matt Cartwright (D-PA). Provide coverage under the Medicare program of hearing aids and related hearing services. HR 6159 (116th Congress), Kids Access to Primary Care Act of 2020, by Rep. Kim Schrier (D-WA). Renew the application of the Medicare payment rate floor to primary care services furnished under the Medicaid program. HR 6179 (116th Congress), Increasing Access to Biosimilars Act of 2020, by Rep. Tony Cardenas (D-CA). Require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program. HR 6214 (116th Congress), by Rep. Ron Kind (D-WI). Provide for coverage of testing for COVID-19 at no cost sharing under the Medicare Advantage program. HR 6218 (116th Congress), Preserving Patient Access to Home Infusion Act, by Rep. Eliot Engel (D-NY). Clarify congressional intent and preserve patient access to home infusion therapy under the Medicare program. HR 6263 (116th Congress), by Rep. John Sarbanes (D-MD). Waive cost sharing under the Medicare program for certain visits relating to testing for COVID-19. HR 6273 (116th Congress), Protecting Vulnerable Americans in Times of Crisis Act of 2020, by Rep. G. K. Butterfield (D-NC). Increase allotments under the Medicaid program for territories of the United States, to provide for a temporary increase in the Federal medical assistance percentage for States under the Medicaid program. HR 6281 (116th Congress), Medicare Wage Index Parity Act of 2020, by Rep. Bill Pascrell (D-NJ). Provides statutory authority for, and extends, a specified methodology used to calculate the minimum Medicare hospital wage index for all-urban states. HR 6282 (116th Congress), Commission on America's Medical Security Act, by Rep. Raul Ruiz (D-CA). Establish a commission to assess, evaluate, and address the dependence of the United States on medications, devices, and medical equipment from foreign countries. HR 6336 (116th Congress), Increasing Hospital Capacity to Fight the Coronavirus Act of 2020, by Rep. Dan Bishop (R-NC). Provide a waiver of payment reductions under the Medicare and Medicaid programs for certain nonapproved capital expenditures undertaken by health care facilities during the COVID-19 emergency. HR 6486 (116th Congress), Care for COVID-19 Act 2.0, by Rep. Raul Ruiz (D-CA). Require the Secretary of Health and Human Services to establish a special enrollment period during the COVID-19 emergency period, to require the Secretary to carry out outreach and educational activities for such special enrollment period, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage without any cost sharing for certain items and services furnished during any portion of such emergency period. HR 6487 (116th Congress), Advancing Connectivity during the Coronavirus to Ensure Support for Seniors Act, by Rep. Jan Schakowsky (D-IL). Increase the ability of nursing facilities to access telehealth services and obtain technologies to allow virtual visits during the public health emergency relating to an outbreak of coronavirus disease 2019 (COVID-19). HR 6583 (116th Congress), by Rep. Chrissy Houlahan (D-PA). Establish a risk corridor program for Medicare Advantage plans during the COVID-19 emergency. HR 6616 (116th Congress), Stronger Medicaid Response to the COVID-19 Pandemic Act, by Rep. Tony Cardenas (D-CA). Allows COVID-19 vaccines and treatment, as well as treatment for conditions that may complicate COVID-19 treatment, for uninsured individuals to be covered under Medicaid during the public health emergency. HR 6640 (116th Congress), Medicare Advantage COVID Treatment Act, by Rep. Debbie Mucarsel-Powell (D-FL). Requires Medicare Advantage (MA) plans to cover specified treatment services relating to COVID-19 without cost-sharing during the public health emergency. HR 6649 (116th Congress), Lower Drug Costs for Seniors During COVID-19 Act of 2020, by Rep. Janice Schakowsky (D-IL). Requires the Centers for Medicare & Medicaid Services to establish a process for prescription drug plans under Medicare and Medicare Advantage to allow enrollees to make coinsurance payments in periodic installments, if the enrollee chooses to obtain the entire prescribed supply of a covered drug in a single fill. HR 6674 (116th Congress), Medicare Crisis Program Act of 2020, by Rep. Pramila Jayapal (D-WA). Ensure access to affordable, comprehensive health insurance benefits for certain uninsured individuals during the COVID-19 emergency, and to ensure adequate coverage of treatments for COVID-19 under the Medicare and Medicaid programs and under group health plans and group or individual health insurance coverage. HR 6698 (116th Congress), Quality Care for Nursing Home Residents and Workers During COVID-19 Act of 2020, by Rep. Jan Schakowsky (D-IL). Improve the quality of care in skilled nursing facilities under the Medicare program and nursing facilities under the Medicare program during the COVID-19 emergency period. HR 6739 (116th Congress), Ensuring Seniors' Access to COVID Treatments Act, by Rep. Sean Casten (D-IL). Requires prescription drug plans under Medicare and Medicare Advantage to cover drugs that are approved to treat COVID-19 without cost-sharing during the public health emergency. HR 6753 (116th Congress), Rural Community Hospital Demonstration Extension Act of 2020, by Rep. Abby Finkenauer (D-IA). Amend the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to extend the rural community hospital demonstration program. HR 6837 (116th Congress), Medicare Accelerated and Advance Payments Improvement Act of 2020, by Rep. Bradley Scott Schneider (D-IL). Modify the accelerated and advance payment programs under parts A and B of the Medicare program during the COVID-19 emergency. HR 6971 (116th Congress), Medical Nutrition Therapy Act of 2020, by Rep. Eliot Engel (D-NY). Expand the availability of medical nutrition therapy services under the Medicare program. HR 7062 (116th Congress), Affordable Insulin for the COVID-19 Emergency Act, by Rep. Maxine Waters (D-CA). Eliminate cost-sharing with respect to coverage of insulin as a covered part D drug and associated medical supplies and to provide mail order access to insulin and such supplies under the Medicare program during the COVID-19 emergency period. HR 7127 (116th Congress), by Rep. G. K. Butterfield (D-NC). Makes technical amendments to the separate payment under the Medicare program for disposable negative pressure wound therapy devices. HR 7154 (116th Congress), Outpatient Therapy Modernization and Stabilization Act, by Rep. Brendan Boyle (D-PA). Improve and ensure ongoing Medicare beneficiary access to outpatient therapy services. HR 7292 (116th Congress), COVID-19 Hospital and Health Provider Loan Forgiveness Act of 2020, by Rep. Marcy Kaptur (D-OH). Provide for forgiveness of certain accelerated and advance payments under parts A and B of the Medicare program. HR 7323 (116th Congress), Medicare Mental Health Inpatient Equity Act of 2019, by Rep. Paul Tonko (D-NY). Eliminate the 190-day lifetime limit on inpatient psychiatric hospital services under the Medicare Program. HR 7338 (116th Congress), by Rep. Liz Cheney (R-WY). Permit the Secretary of Health and Human Services to waive requirements relating to the furnishing of telehealth services under the Medicare program. HR 7391 (116th Congress), by Rep. Mikie Sherrill (D-NJ). Remove certain geographic and originating site restrictions on the furnishing of telehealth services under the Medicare program.

Client expense: Not reported · Firm income: Not reported

HR 6218

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

BLUE CROSS AND BLUE SHIELD OF FLORIDA INCclient→BLUE CROSS AND BLUE SHIELD OF FLORIDA INC

2020 · second_quarter · Medicare/Medicaid

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Medicare Advantage; Medicaid Expansion; Medicaid; Medicare Data Sharing; Privacy; Medicare Prescription Drug Prices; CMS; Generic Drugs (CREATES Act); Drug Approval; HELP Cost Reduction Package; CHIP, MACRA; Provider Funding; Medicaid FMAP Increase; Coronavirus Medicaid Response; Rate Notice and Call Letter HR 3107 (116th Congress), Improving Seniors Timely Access to Care Act of 2019, by Rep. Suzan DelBene (D-WA). Establish requirements with respect to the use of prior authorization under Medicare Advantage plans. HR 5534 (116th Congress), Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019, by Rep. Ron Kind (D-WI). Provide for extended months of Medicare coverage of immunosuppressive drugs for kidney transplant patients. HR 5582 (116th Congress), Parental Accessibility Rights for Emergency and Negligent Treatment Act, by Rep. Gregory Murphy (R-NC). Expands the scope of advance directive policies and related disclosures for providers under Medicaid and the Children's Health Insurance Program (CHIP). HR 5693 (116th Congress), Primary Health Services Enhancement Act, by Rep. Ron Kind (D-WI). Expand Medicare Rural Health Clinic Services and Federally Qualified Health Center Services to include physical therapy services. HR 5741 (116th Congress), Strengthening Innovation in Medicare and Medicaid Act, by Rep. Terri Sewell (D-AL). Clarify parameters for model testing and add accountability to model expansion under the Center for Medicare and Medicaid Innovation. HR 5833 (116th Congress), by Rep. Bob Latta (R-OH). Permit the use of certain psychological evaluation via telehealth for Medicare coverage of neurostimulation services for the treatment of chronic pain. HR 5882 (116th Congress), GENE Therapy Payment Act, by Rep. Kurt Schrader (D-OR). Provide States with the option under the Medicaid program to pay for covered outpatient drugs through risk-sharing value-based agreements. HR 5897 (116th Congress), Preventing Abuse and Neglect of Vulnerable Americans Act of 2020, by Rep. Ruben Gallego (D-AZ). Requires the Centers for Medicare & Medicaid Services (CMS) to publish specified information on its website relating to deficiencies of Medicaid intermediate care facilities for individuals with intellectual disabilities, including information regarding inspections, complaints, and administrative actions. HR 5900 (116th Congress), Accelerating Kids' Access to Care Act, by Rep. Joseph Kennedy (D-MA). Requires state Medicaid programs to establish a process through which qualifying out-of-state providers may enroll as participating providers without undergoing additional screening requirements. HR 6098 (116th Congress), by Rep. Nanette Diaz Barragan (D-CA). Allow States to expand income eligibility standards under the Childrens Health Insurance Program. HR 6147 (116th Congress), Help Extend Auditory Relief (HEAR) Act of 2020, by Rep. Matt Cartwright (D-PA). Provide coverage under the Medicare program of hearing aids and related hearing services. HR 6159 (116th Congress), Kids Access to Primary Care Act of 2020, by Rep. Kim Schrier (D-WA). Renew the application of the Medicare payment rate floor to primary care services furnished under the Medicaid program. HR 6179 (116th Congress), Increasing Access to Biosimilars Act of 2020, by Rep. Tony Cardenas (D-CA). Require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program. HR 6214 (116th Congress), by Rep. Ron Kind (D-WI). Provide for coverage of testing for COVID-19 at no cost sharing under the Medicare Advantage program. HR 6218 (116th Congress), Preserving Patient Access to Home Infusion Act, by Rep. Eliot Engel (D-NY). Clarify congressional intent and preserve patient access to home infusion therapy under the Medicare program. HR 6263 (116th Congress), by Rep. John Sarbanes (D-MD). Waive cost sharing under the Medicare program for certain visits relating to testing for COVID-19. HR 6273 (116th Congress), Protecting Vulnerable Americans in Times of Crisis Act of 2020, by Rep. G. K. Butterfield (D-NC). Increase allotments under the Medicaid program for territories of the United States, to provide for a temporary increase in the Federal medical assistance percentage for States under the Medicaid program. HR 6281 (116th Congress), Medicare Wage Index Parity Act of 2020, by Rep. Bill Pascrell (D-NJ). Provides statutory authority for, and extends, a specified methodology used to calculate the minimum Medicare hospital wage index for all-urban states. HR 6282 (116th Congress), Commission on America's Medical Security Act, by Rep. Raul Ruiz (D-CA). Establish a commission to assess, evaluate, and address the dependence of the United States on medications, devices, and medical equipment from foreign countries. HR 6336 (116th Congress), Increasing Hospital Capacity to Fight the Coronavirus Act of 2020, by Rep. Dan Bishop (R-NC). Provide a waiver of payment reductions under the Medicare and Medicaid programs for certain nonapproved capital expenditures undertaken by health care facilities during the COVID-19 emergency. HR 6486 (116th Congress), Care for COVID-19 Act 2.0, by Rep. Raul Ruiz (D-CA). Require the Secretary of Health and Human Services to establish a special enrollment period during the COVID-19 emergency period, to require the Secretary to carry out outreach and educational activities for such special enrollment period, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage without any cost sharing for certain items and services furnished during any portion of such emergency period. HR 6487 (116th Congress), Advancing Connectivity during the Coronavirus to Ensure Support for Seniors Act, by Rep. Jan Schakowsky (D-IL). Increase the ability of nursing facilities to access telehealth services and obtain technologies to allow virtual visits during the public health emergency relating to an outbreak of coronavirus disease 2019 (COVID-19). HR 6583 (116th Congress), by Rep. Chrissy Houlahan (D-PA). Establish a risk corridor program for Medicare Advantage plans during the COVID-19 emergency. HR 6616 (116th Congress), Stronger Medicaid Response to the COVID-19 Pandemic Act, by Rep. Tony Cardenas (D-CA). Allows COVID-19 vaccines and treatment, as well as treatment for conditions that may complicate COVID-19 treatment, for uninsured individuals to be covered under Medicaid during the public health emergency. HR 6640 (116th Congress), Medicare Advantage COVID Treatment Act, by Rep. Debbie Mucarsel-Powell (D-FL). Requires Medicare Advantage (MA) plans to cover specified treatment services relating to COVID-19 without cost-sharing during the public health emergency. HR 6649 (116th Congress), Lower Drug Costs for Seniors During COVID-19 Act of 2020, by Rep. Janice Schakowsky (D-IL). Requires the Centers for Medicare & Medicaid Services to establish a process for prescription drug plans under Medicare and Medicare Advantage to allow enrollees to make coinsurance payments in periodic installments, if the enrollee chooses to obtain the entire prescribed supply of a covered drug in a single fill. HR 6674 (116th Congress), Medicare Crisis Program Act of 2020, by Rep. Pramila Jayapal (D-WA). Ensure access to affordable, comprehensive health insurance benefits for certain uninsured individuals during the COVID-19 emergency, and to ensure adequate coverage of treatments for COVID-19 under the Medicare and Medicaid programs and under group health plans and group or individual health insurance coverage. HR 6698 (116th Congress), Quality Care for Nursing Home Residents and Workers During COVID-19 Act of 2020, by Rep. Jan Schakowsky (D-IL). Improve the quality of care in skilled nursing facilities under the Medicare program and nursing facilities under the Medicare program during the COVID-19 emergency period. HR 6739 (116th Congress), Ensuring Seniors' Access to COVID Treatments Act, by Rep. Sean Casten (D-IL). Requires prescription drug plans under Medicare and Medicare Advantage to cover drugs that are approved to treat COVID-19 without cost-sharing during the public health emergency. HR 6753 (116th Congress), Rural Community Hospital Demonstration Extension Act of 2020, by Rep. Abby Finkenauer (D-IA). Amend the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to extend the rural community hospital demonstration program. HR 6837 (116th Congress), Medicare Accelerated and Advance Payments Improvement Act of 2020, by Rep. Bradley Scott Schneider (D-IL). Modify the accelerated and advance payment programs under parts A and B of the Medicare program during the COVID-19 emergency. HR 6971 (116th Congress), Medical Nutrition Therapy Act of 2020, by Rep. Eliot Engel (D-NY). Expand the availability of medical nutrition therapy services under the Medicare program. HR 7062 (116th Congress), Affordable Insulin for the COVID-19 Emergency Act, by Rep. Maxine Waters (D-CA). Eliminate cost-sharing with respect to coverage of insulin as a covered part D drug and associated medical supplies and to provide mail order access to insulin and such supplies under the Medicare program during the COVID-19 emergency period. HR 7127 (116th Congress), by Rep. G. K. Butterfield (D-NC). Makes technical amendments to the separate payment under the Medicare program for disposable negative pressure wound therapy devices. HR 7154 (116th Congress), Outpatient Therapy Modernization and Stabilization Act, by Rep. Brendan Boyle (D-PA). Improve and ensure ongoing Medicare beneficiary access to outpatient therapy services. HR 7292 (116th Congress), COVID-19 Hospital and Health Provider Loan Forgiveness Act of 2020, by Rep. Marcy Kaptur (D-OH). Provide for forgiveness of certain accelerated and advance payments under parts A and B of the Medicare program. HR 7323 (116th Congress), Medicare Mental Health Inpatient Equity Act of 2019, by Rep. Paul Tonko (D-NY). Eliminate the 190-day lifetime limit on inpatient psychiatric hospital services under the Medicare Program. HR 7338 (116th Congress), by Rep. Liz Cheney (R-WY). Permit the Secretary of Health and Human Services to waive requirements relating to the furnishing of telehealth services under the Medicare program. HR 7391 (116th Congress), by Rep. Mikie Sherrill (D-NJ). Remove certain geographic and originating site restrictions on the furnishing of telehealth services under the Medicare program.

Client expense: $350,000 · Firm income: Not reported

HR 6218

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office